دورية أكاديمية
أعرض في EDS

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma

التفاصيل البيبلوغرافية
العنوان: Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
المؤلفون: Yu-Jie Xu MD, Zhi-Cheng Lai MD, Min-Ke He MD, Xiao-Yun Bu MD, Huan-Wei Chen MD, Yuan-Min Zhou MD, Li Xu MD, Wei Wei MD, Yao-Jun Zhang MD, Min-Shan Chen MD, Rong-Ping Guo MD, Ming Shi MD, Qi-Jiong Li MD
المصدر: Technology in Cancer Research & Treatment, Vol 20 (2021)
بيانات النشر: SAGE Publishing, 2021.
سنة النشر: 2021
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Purpose: Immunotherapy combined with chemotherapy have synergistic effects in multiple malignancies. We aimed to compare the efficacy and safety of toripalimab plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib in advanced hepatocellular carcinoma (HCC). Materials and Methods: We conducted this retrospective study at 3 hospitals in China and eligible patients were 18 years or older and had a primary diagnosis of unresectable HCC with macroscopic vascular invasion and/or extrahepatic spread. These patients were treated with toripalimab plus HAIC or lenvatinib monotherapy. The primary endpoint was progression-free survival (PFS) and the secondary endpoints were overall survival (OS), disease control rate per response evaluation criteria in solid tumors (RECIST) 1.1, and objective response rate (ORR) per RECIST 1.1. The results were compared by Student's test or the chi-square test, and the survival curves were calculated by the Kaplan–Meier method, and propensity-score matching (PSM) was used to reduce bias. Results: A total of 118 patients were recruited for this study: 53 in the TorHAIC group and 65 in the lenvatinib group. We found that the TorHAIC group showed a longer PFS (9.3 [95% CI, 7.81-10.8] vs 4.8 months [95% CI, 3.31−6.29]; hazard ratio [HR] = 0.57, 95% CI, 0.38-0.85; p = .006), a longer OS (17.13 [95% CI, 13.99−20.27] vs 10.1 months [95% CI, 8.14−12.06]; HR = 0.5, 95% CI, 0.31 − 0.81; p = .005), a higher disease control rate (86.8% vs 69.2%, p = .002) and a higher ORR (47.2% vs 9.2%, p
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1533-0338
15330338
Relation: https://doaj.org/toc/1533-0338
DOI: 10.1177/15330338211063848
URL الوصول: https://doaj.org/article/cbb3d7bec5794c30ba745d6d3ade94bd
رقم الأكسشن: edsdoj.bb3d7bec5794c30ba745d6d3ade94bd
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:15330338
DOI:10.1177/15330338211063848